Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Liposarcoma, Myxoid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Graft vs Host Disease 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 12Methotrexate 9Antilymphocyte Serum 9fludarabine phosphate 8Tacrolimus 8Cyclosporine 8Mycophenolic Acid 6Whole-Body Irradiation 5Radiotherapy 5Busulfan 5thymoglobulin 4Sirolimus 4Methylprednisolone 4Filgrastim 4Alemtuzumab 4fludarabine 3Transplantation 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Cord Blood Stem Cell Transplantation 3Thiotepa 2Therapeutics 2Stem Cell Transplantation 2Muromonab-CD3 2Immunosuppression Therapy 2Calcineurin Inhibitors 2visilizumab 1milatuzumab 1itacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Graft vs Host Disease × INCB039110 × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡